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A B S T R A C T
Various biotin-modified liposomes incorporated with docetaxel (DTX) were prepared to study
the effect of surface biotin density on the pharmacokinetic profile of the liposome. Four types
of liposomes such as PEG modified liposome (PDL), 0.5% (mol) biotin modified liposome
(0.5BDL), 1% (mol) biotin modified liposome (1BDL) and 2% (mol) biotin modified liposome
(2BDL) were prepared using thin film dispersion method.The prepared liposomes were char-
acterized by measuring encapsulation efficiency (EE), particle size, Zeta-potential, physical
stability and drug release profiles in vitro. MTT assay was performed to elevate the cyto-
toxicity of liposomes on MCF-7 cells. In vivo evaluation was further performed to investigate
the effect of biotin surface density on the pharmacokinetic profiles. All the prepared lipo-
somes exhibited high encapsulation efficiency, small particle size, narrow particle distribution
and sustained release profiles in vitro. In MTT assay, 0.5BDL showed largest tumor cell tox-
icity, compared with DTX solution. All liposomes containing DTX showed prolonged blood
circulation in vivo, and 0.5BDL showed the longest circulation time among the biotin modi-
fied liposome. Surface modification of liposome had a negative impact on the circulation
of liposomes in the blood, which needs to be considered when designing the ligand medi-
ated targeting delivery systems. A proper amount of biotin liposome with 0.5% molar ratio
is expected to produce the best anti-tumor effect.
© 2016 Production and hosting by Elsevier B.V. on behalf of Shenyang Pharmaceutical









Docetaxel, a second-generation semi-synthetic taxane deriva-
tive has shown dramatic antitumor activities, mostly against
various human cancers such as ovarian carcinoma, advanced
breast cancer, lung cancer and head/neck cancer [1]. Cur-
rently, docetaxel is formulated using Tween80 and ethanol
(50:50,v/v) as solvent; however, its clinical use is limited due
to its side effects related to formulation, such as neutropenia,
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peripheral neuropathy and hypersensitivity reactions [1,2].
Therefore, there is a strong rationale for reformulating docetaxel
using a safer vehicle than Tween80.
Recently, many carriers have been studied, such as
nanoparticle-aptamer, bioconjugates [3], DTX loaded lipo-
somes [4], pegylated liposomes [4,5], N-palmitoyl chitosan
anchored DTX liposomes [6], and pegylated immunoliposomes
[7]. Liposomes with spherical lipid bilayer structures are one
of the most successful drug carriers in drug delivery systems;
however, they are prone to be taken up by reticuloendothe-
lial system (RES) cells in liver and spleen [8,9]. As is well known
that PEG modified liposomes exhibit a long circulation prop-
erty in the blood and accumulate in tumor via passive targeting
[4,10,11], increasing evidence has suggested that the selectiv-
ity of PEGmodified liposomes is far from satisfaction.Therefore,
many researchers have been focusing on developing active tar-
geting drug delivery systems, in which many ligands have been
introduced to the surface of drug carrier, such as folic acid [12],
antibody [13] and integrin αvβ3 [14]. Biotin, a member of the
vitamin family (vitamin H), is a growth promoter of cells. Its
ligand in cancerous tumors is higher than in normal tissue [15]
because rapid proliferation of cancer cells requires extra biotin.
Some cancer cells including JC, Colo-26, P815 and MCF-7 over-
express biotin-specific receptors [16,17], which are responsible
for the uptake of essential nutrients such as biotin, lipoate, pan-
tothenate [18] and peptides [19]. Biotin has been considered
as a promising ligand for active targeting [16,20–22]; Yang et al.
prepared biotin–dendrimer conjugate, which exhibited much
higher cellular uptake into Hela cells than the dendrimer
without biotin modification [23]. Biotinylated pullulan acetate
nanoparticles was prepared by Na, which has been shown
strong adsorption to the HepG2 cells [24]. Biotin-conjugated
polymericmicelles could effectively release doxorubicin in acidic
tumor cells compared to that without biotin [25].
However, the effect of biotin modification and density on
cytotoxicity and pharmacokinetic profiles of the carriers has
not been explored to date. Previous studies have shown that
the cellular uptake increased with the increase of ligand density
on the surface of particles [26–28]. However, dense surface cov-
erage of ligand may not produce expected improvements in
cellular uptake [29,30]. Moreover, some studies have shown that
the insertion of ligand resulted in faster clearance of lipo-
somes from plasma, which compromised the accumulation of
liposomes in tumor via EPR effect [31,32]. It was reported that
the 2.56 mol% NGR (asparagine–glycine–arginine amino acid
sequence) resulted in lower total tumor accumulation than the
formulation with only 0.64 mol% NGR [33].
As known, the success of an active targeting strategy relied
heavily on the accumulation of the carriers at tumor site via
passive targeting. If the drug loaded carriers were quickly elimi-
nated in vivo, the total tumor accumulation of carriers will be
decreased. The pharmacokinetic profiles of the active target-
ing formulation are important factors that need to be considered
to achieve successive active targeting.
The researches on the effect of biotin density of liposome
on cytotoxicity and pharmacokinetic profiles were absent. In
this study, biotin was conjugated to PEG chains on the surface
of liposomes containing DTX, in an attempt to improve cancer
targeting. DTX loaded liposomes modified with different biotin
density were prepared to investigate the effect of biotin density
on the cytotoxicity and the pharmacokinetic profiles of lipo-
somes in blood.This study will lay a foundation for optimization
of liposome formulation for further in vivo evaluation.
2. Materials and methods
2.1. Materials
Docetaxel was purchased from Jiansu Hengrui Medicinal Co.,
Ltd (Jiangsu, China). Cholesterol (Chol) was purchased from
Tianjin Bodi Chemical Industry Co. (Tianjin, China). Soy phos-
phatidylcholine (Spc) was purchased from Shanghai Taiwei
Pharmacetical Co. (Shanghai, China). Dichloromethane was pur-
chased from Tianjin Jingxi Chemical Industry Co. (Tianjin,
China). Disteroylphophatidyl ethanolamine methoxypoly-
ethylene glycol conjugate (DSPE-PEG2000) was purchased from
Nippon Fine Chemical Co., Ltd (Kobe, Japan) and Biotin-PEG2000-
DSPE was purchased from Creative PEG Works Co. (Winston-
Salem, NC, USA). Methanol, acetonitrile and tert-butyl methyl
ether were of high-performance liquid chromatography (HPLC)
grade, all other regents and solvents used were of analytical
grade. Sprague–Dawley rats (200 ± 20 g) were supplied by the
Laboratory Animal Center of Shenyang Pharmaceutical Uni-
versity (Shenyang, China).All animal procedures were approved
by the Animal Ethics Committee of Shenyang Pharmaceuti-
cal University.
2.2. Preparation of liposomes
Liposomes were prepared by thin-film hydrationmethod. Briefly,
to prepare PEG modified liposome (PDL), Spc Chol (Spc: Chol,
9:2, molar ratio) and DSPE-PEG (4% mol) as well as DTX (1:18,
mass ratio) were first dissolved in dichloromethane solu-
tions. The mixture was placed in a round-bottomed flask and
the solvent was removed by rotary evaporation at 37 °C under
vacuum to obtain the dry film. Afterward, the film was hy-
drated with pH 7.4 PBS buffer in a water bath at 40 °C with
stirring for 20 min until a homogenous liposome suspension
was obtained. The suspension was then sonicated with a ul-
trasonic cell disruptor, and the pulse function was 220w, on
1 s and off 1 s for 2 min. Polycarbonate filters, with a pore size
of 220 nm were used to decrease the size of liposomes. The
liposomes were purified by centrifugating at 15 000 × g for
15 min. Biotin modified liposomes (0.5BDL, 1BDL, 2BDL) were
prepared using the samemethod mentioned above except that
0.5%, 1% and 2% (mol) of DSPE-PEG2000 were used respectively.
2.3. Characterization of liposomes
The DTX concentration was determined by high perfor-
mance liquid chromatography (HPLC). In detail, the analysis
was performed with a Hitachi HPLC system (UV Detector L-2400,
Pump L-2130, Hitachi,Tokyo, Japan), equipped with a 20 μl loop
and a reversed-phase column (Hypersil, ODS, 4.6 × 250 mm,
5 μm).The mobile phase was made up of acetonitrile and water
(60:40; v/v) at a flow rate of 1 ml/min, and the DTX was de-
tected at a wavelength of 228 nm. Methanol was used before
analysis as a demulsifier. The encapsulation efficiency (EE%)
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and drug loading content (LC%) were calculated using equa-












% %= ⎛⎝⎜ ⎞⎠⎟ × 100 (2)
where, We is the amount of drug encapsulated, Wadd is the
amount of drug used and Wt is total amount of encapsulated
drug and liposome.
The diameter and Zeta potential of the liposomes were de-
termined by Zetasizer3000 (Malven Instruments Ltd., UK).
Intensity autocorrelation was measured at a scattering angle
of 90 degrees at room temperature.
The morphological feature of the liposomes was observed
with a transmission electron microscope (TEM) (JEM-1200EX,
JEOL Ltd., Japan) at 80 kV.A drop of liposomal sample was placed
on a copper grid, excess water was blotted with a piece of filter
paper and a drop of 1% phosphotungstic acid was added for
negative staining.
Initial stability of liposomes was evaluated by detecting
leakage of DTX from liposomes at 4 °C. Encapsulation effi-
ciency of four liposomes was detected by HPLC at 1, 2, 3, 4, 5,
7, 10, 13 and 15 days after preparation. The leakage rate (LR%)




n% %= − ⎛⎝⎜ ⎞⎠⎟ ×1 1001 (3)
where EEn is the encapsulation efficiency detected at n day, and
EE1 is the encapsulation efficiency detected at the first day.
In vitro release of DTX from liposomes was determined using
dialysis method with a pharmaceutical dissolution tester at
37 °C. The samples were put into dialysis bags (COMW: 8000–
14,000), and PBS (80 ml, PH7.4) containing 0.5% (v/v) Tween80
was used as the release medium.Tween80 was added to ensure
the sink condition. The stirring speed is 50 rpm. At each time
point, 2 ml release medium was withdrawn and replaced with
fresh PBS.The concentration of DTX in the release mediumwas
determined using HPLC.The mobile phase was made up of ace-
tonitrile and water (52:48, v/v) at a flow rate of 1 ml/min.
2.4. Cytotoxicity in vitro
The human breast cell line MCF-7 (purchased from Shanghai
Fuleibao Bio-Tech Co., Ltd) was maintained in Dulbecco’s modi-
fied Eagle’s medium (DMEM) containing 10% fetal bovine serum
and 0.1% antibiotics (penicillin streptomycin) in a 5% CO2
humidified atmosphere at 37 °C. The MTT assay was used to
test the cytotoxicity in vitro; the cells were seeded at 8 × 103 cells/
well in 96 well plates and incubated for 24 h. The cells were
then incubated in 96 well plates at 37 °C for 24 h, 48 h, and 72 h
in the presence of a series of concentration of formulations,
including DTX solution (FD), PDL, 0.5BDL, 1BDL, and 2BDL.The
cells incubated in mediumwithout any drug or liposomes were
used as controls. 20 μl of MTT (5 mg/ml) were added at the end
of incubation period. The plates were incubated for an addi-
tional 4 h. DMSO (150 μl) were added to dissolve the formazan
crystals and the absorbance value was determined at wave-
lengths of 490 nm.
2.5. Pharmacokinetic studies
SD rats were divided into five groups randomly (three rats per
group). PDL, 0.5BDL, 1BDL, and 2BDL were i.v. administration
at a dose of 10 mg/kg and DTX in tween80 (FD) was chosen as
control group. Blood samples were collected at 5 min, 10 min,
15 min, 30 min, 45 min, 1 h, 2 h, 4 h, 8 h, 12 h and 24 h. The
samples were then centrifuged at 5000 rpm for 10 min to sepa-
rate the plasma; 10 μl of paclitaxel (10 μg/ml) used as internal
standard was added into 200 μl of plasma. The mixture was
vortexed for 30 s twice to mix well, and then 2 ml of tert-
butyl methyl ether was added.Then the mixture was sonicated
for 3 min, and vortexed for 5 min. Clear supernatant was
obtained by centrifugating at 10,000 rpm for 5 min. The su-
pernatant was dried with nitrogen gas and reconstituted in
100 μl of methanol.The concentration of DTX in blood wasmea-
sured using HPLC. A reversed-phase column (Hypersil, ODS,
4.6 × 250 mm, 5 μm) was used.The mobile phase was made up
of acetonitrile and water (57:43, v/v) at a flow rate of 1 ml/min.
The DTX detection was performed at a wavelength of 228 nm.
Pharmacokinetic parameters were determined using the soft-
ware DAS2.0. The significance of the difference was analyzed
by ANOVA models with Statistical Program for Social Sci-
ences (SPSS 11.0) and the significant level was set at 0.05.
3. Results and discussion
3.1. Characterization of liposomes
Encapsulation efficiency (EE%), drug loading content (LC%),
mean diameter with poly dispersion index (PDI) and zeta po-
tential of four liposomes were displayed in Table 1. It could be
seen that incorporation of Biotin-PEG2000-DSPE into the mem-
brane increased the mean diameter and slightly decreased the
Zeta potential of the liposomes. Morphology of four lipo-
somes observed by TEM is shown in Fig. 1. The double
Table 1 – Characterization of four kinds of liposomes (n = 3).
PDL 0.5BDL 1BDL 2BDL
EE (%) 94.60 ± 1.889 96.19 ± 2.515 91.92 ± 2.604 88.11 ± 2.079
LC (%) 3.950 ± 0.237 4.001 ± 0.321 3.808 ± 0.425 3.613 ± 0.385
Diameter (nm) 97.99 ± 14.32 133.2 ± 4.644 135.1 ± 3.570 145.0 ± 5.015
PDI 0.266 ± 0.048 0.280 ± 0.007 0.323 ± 0.003 0.264 ± 0.032
Zeta potential (mv) −30.00 ± 1.150 −25.23 ± 0.473 −24.20 ± 1.212 −20.40 ± 0.361
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membrane of the liposomes could be seen clearly and no drug
crystal was visible.The leakage rate (Fig. 2) of all liposomes was
less than 25% at 4 °C in the hydrated state for 15 days. The
release behavior of DTX from four liposomes and free DTX in
the release medium were shown in Fig. 3. The four liposomes
(PDL, 0.5BDL, 1BDL, 2BDL) released 69.12 ± 9.98%, 57.44 ± 0.37%,
54.49 ± 6.58% and 52.37 ± 3.62% of DTX respectively at 96 h in
comparison with free DTX (96.15 ± 0.48% at 6 h), indicating that
four liposomes had a sustained release profile.
Docetaxel is a potent anticancer drug and its use is re-
stricted by its poor aqueous solubility where addition ofTween80
to enhance DTX solubility was associated with its side effects
[1]. Liposomes are capable of increasing the aqueous solubil-
ity of DTX. Moreover, biotin was used to modify the liposomes
with an aim to increase the DTX accumulation in tumor site.
All the prepared liposomes had high encapsulation effi-
ciency and drug loading rate. Mean diameter of liposomes
increased with the incorporation of Biotin-PEG2000-DSPE due to
the interaction of Biotin at the end of Biotin-PEG2000-DSPE and
the swelling resulting from the hydrophilic property of biotin
[24].The particulate carrier systems with a diameter larger than
200 nm are known to induce nonspecific scavenging by mono-
cytes and the reticuloendothelial system (RES) [34,35]. It was
reported that some tumor vessels could cause extravasation
of particulates with a diameter less than 400 nm [5,36]. The li-
posomes with a diameter around 100 nm extravasated much
easier than bigger ones with a diameter ranging from 200 to
400 nm [37,38]. The liposomes prepared in this study were
found to have a diameter between 97.99 ± 14.32 nm and
145.0 ± 5.015 nm, which were not expected to be removed by
the RES. Biotinylation of liposome did not markedly change the
Zeta potential; although biotin is known to possess a posi-
tive charge, the result is in agreement with an earlier study
[39].
The therapeutic effect of drug in carriers is highly depen-
dent on the release rate of the drug from the carrier. If the drug
leaks from the carrier too rapidly, the carrier will lose most of
the loaded drug before it reaches the diseased site, leading to
the compromised therapeutic effect. In our study, we com-
pared the DTX release behavior of FD and all liposomes. As
shown in Fig. 3, four liposomes released DTX slower than FD.
The sustained release of DTX from liposomes was probably at-
tributed to the encapsulation by the bilayer membrane of
liposomes.
3.2. MTT assay
Cell viability of 24 h, 48 h, and 72 h after adding empty lipo-
some (EL), FD, PDL, 0.5BDL, 1BDL and 2BDL are shown in Fig. 4(A,
B, C). IC50 was calculated and the results were shown in Table 2.
The IC50 of liposomes were higher than FD (P < 0.01) after 24 h
and 48 h incubation. However, 0.5BDL showed lower IC50 than
FD at 72 h (P < 0.01). Compared with 0.5BDL, both 1BDL and 2BDL
showed significantly higher IC50 (P < 0.01) and there is no sig-
nificant difference between 1BDL and 2BDL (P > 0.05).The result
suggested that empty liposome has no inhibition effect on cell
growth, and cell viability decreased with increasing of the con-
centration of DTX. For all liposomes and FD, IC50 decreased with
the increasing of incubation time.
Fig. 1 – Transmission electron microscopy of PDL (A);
0.5BDL (B); 1BDL (C) and 2BDL (D) (×40,000).
Fig. 2 – Leakage rate of four kinds of liposomes at 4 °C
(n = 3).
Fig. 3 – Drug release from FD and four kinds of liposomes
in PBS (PH 7.4) containing 0.5% Tween80 (n = 3).
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Itwas found that drug concentration and exposure timewere
closely related to cytotoxicity of all formulations. This result
was in agreement with previous research [40,41]. The higher
cell viability of liposomes than FD at 24 h and 48 h is probably
related to the doublemembrane of liposomeand the steric effect
of PEG chains, which, first, can inhibit the release of drug from
carriers, and second, can prevent liposomes from interacting
with cells. In addition, liposomes may delay internalization of
drug in cells due to the negative charge on the surface of li-
posomes. Liposomes with negative charge generally exhibit
stronger binding than neutral ones because of the existence
of a membrane receptor recognizing negatively charged par-
ticles [42]. Fig. 3 suggested that among liposomes, PDL had the
highest drug release rate, which induced the highest cytotox-
icity at 24 h. The biotin receptor on the surface of MCF-7 may
play a role in uptaking the liposomes into the cells and causing
the cytotoxicity. It was found that IC50 of 1BDL and 2BDL showed
no significant difference in the cytotoxicity. But IC50 value of
0.5BDL is nearly two times and three times lower.Higher biotin
density on the liposomes failed to show higher cytotoxicity.
This is consistent with the findings reported by other research
groups [43,44].Thismight be attributed to the internalized ligand
molecules leading to a down-regulation or ‘shut-off’ of the re-
ceptor recycling system.The ligands conjugated liposomesmay
contribute to the intracellular ligandconcentrationandare there-
fore responsible for the saturation and ‘shut-off’ of the receptor
uptake pathway. Liposomeswithmore targeting ligandswould
lead to more intracellular ligand content than those with less
targeting ligands.This could result in a decreased cytotoxicity
when more ligands are utilized [43]. An alternative explana-
tion is the possible existence of DSPE-PEG2000-Biotin micelles
formed at higher number of targeting ligand.The biotin modi-
fied micelles would compete with the receptors and prevent
biotin modified liposomes binding to the receptors.
3.3. Pharmacokinetic studies
Mean plasma concentration–time profiles of DTX after i.v. ad-
ministration of DTX solution and four liposomes at a dose of
10 mg/kg was shown in Fig. 5. The main pharmacokinetic pa-
rameters were summarized in Table 3. When DTX was
encapsulated in liposomes, the pharmacokinetic parameters
were clearly different from those of FD. The AUC and the MRT
were significantly increased, and the plasma clearance (CL) was
reduced significantly.The AUC of liposomes (PDL; 0.5BDL; 1BDL
and 2BDL) were 10.86 times, 4.456 times, 2.689 times and 3.976
times higher than FD (3.791 ± 1.375 mg/l·h). The MRT of lipo-
somes (PDL,0.5BDL, 1BDL and 2BDL) were 14.89 times, 4.755 times,
1.973 times and 1.851 times higher than FD (3.573 ± 2.121h). In
comparison with FD, CL of liposomes were 0.087 times, 0.208
times, 0.234 times and 0.352 times smaller. Among liposomes
PDL presented the longest MRT, the largest AUC and the lowest
CL, indicating a long circulation time. Compared with PDL, the
biotinmodified liposomeswith different density exhibited a rela-
tively smallerAUC,MRT and larger CL.Among the biotinmodified
liposomes, 0.5BDL showed best stability in blood circulation and
a higher chance to exert biotin mediated endocytosis.
The pharmacokinetic data are shown in Table 3. It can be
observed from Table 3 that the biotin modified liposomes pre-
sented shorter circulation time and smaller AUC and MRT.
Among the biotin modified liposomes, 0.5BDL showed relatively
longer circulation time, larger AUC andMRT. Biotin-PEG2000-DSPE
chains may cover parts of DSPE-PEG2000, leading to less pro-
tection effect of PEG. In addition, biotin as a ligand at the end
Fig. 4 – Viability of MCF-7 after incubation with FD and four
kings of liposomes. Data are presented as Mean ± SD
(n = 5–6).
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of the PEG chains may be recognized by cell membrane re-
ceptor in blood and result in faster elimination from blood.
Previous studies suggested that nanoparticles should be small,
slightly negatively charged and covered with a protective PEG
layer to achieve passive targeting [11]. Our study further in-
dicates that the surface density of ligand will have a negative
impact on the blood circulation of nanocarriers in vivo. Studies
on tumor-bearing rat need to be further investigated to elu-
cidate the active targeting efficiency.
4. Conclusions
The biotin ligand density on the surface of liposome has an
impact on the cytotoxicity and pharmacokinetic of lipo-
somes. The cytotoxicity of biotin conjugated liposomes
decreased with an increase in biotin surface density.The elimi-
nation of biotin conjugated liposomes from blood was increased
with increasing of biotin surface density. The ligand density
of the active targeting liposomes needs to be optimized to
achieve successful targeting.
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